Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-8 of 8 (Search time: 0.005 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2016Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trialNicholls, S.; Puri, R.; Anderson, T.; Ballantyne, C.; Cho, L.; Kastelein, J.; Koenig, W.; Somaratne, R.; Kassahun, H.; Yang, J.; Wasserman, S.; Scott, R.; Ungi, I.; Podolec, J.; Ophuis, A.; Cornel, J.; Borgman, M.; Brennan, D.; Nissen, S.
2014The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011Ray, K.; Kastelein, J.; Matthijs Boekholdt, S.; Nicholls, S.; Khaw, K.; Ballantyne, C.; Catapano, A.; Reiner, Ž.; Lüscher, T.
2014Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 studySjouke, B.; Langslet, G.; Ceska, R.; Nicholls, S.; Nissen, S.; Öhlander, M.; Ladenson, P.; Olsson, A.; Hovingh, G.; Kastelein, J.
2013Effect of aliskiren on progression of coronary disease in patients with prehypertension: The AQUARIUS randomized clinical trialNicholls, S.; Bakris, G.; Kastelein, J.; Menon, V.; Williams, B.; Armbercht, J.; Brunel, P.; Nicolaides, M.; Hsu, A.; Hu, B.; Fang, H.; Puri, R.; Uno, K.; Kataoka, Y.; Bash, D.; Nissen, S.
2015Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk? CETP inhibition as a strategy to reduce cardiovascular risk: The pro caseBarter, P.; Nicholls, S.; Kastelein, J.; Rye, K.
2015Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: insights from AQUARIUSPuri, R.; Nissen, S.; Menon, V.; Shao, M.; Hsu, A.; Bakris, G.; Kastelein, J.; Williams, B.; Armbrecht, J.; Brunel, P.; Kataoka, Y.; Nicholls, S.
2014Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trialNicholls, S.; Kastelein, J.; Schwartz, G.; Bash, D.; Rosenson, R.; Cavender, M.; Brennan, D.; Koenig, W.; Jukema, J.; Nambi, V.; Wright, R.; Menon, V.; Lincoff, A.; Nissen, S.
2018Effect of evolocumab on coronary plaque compositionNicholls, S.; Puri, R.; Anderson, T.; Ballantyne, C.; Cho, L.; Kastelein, J.; Koenig, W.; Somaratne, R.; Kassahun, H.; Yang, J.; Wasserman, S.; Honda, S.; Shishikura, D.; Scherer, D.; Borgman, M.; Brennan, D.; Wolski, K.; Nissen, S.